Volume 12, Number 10—October 2006
Dispatch
ICD-9 Codes and Surveillance for Clostridium difficile–associated Disease
Erik R. Dubberke*
, Kimberly Reske*, L. Clifford McDonald†, and Victoria Fraser*‡
, Kimberly Reske*, L. Clifford McDonald†, and Victoria Fraser*‡
Table 2
Comparison of antimicrobial treatment for Clostridium difficile–associated disease among patient admissions with a positive C. difficile–toxin assay (CDTA+) and patients without a positive toxin assay but with ICD-9 code for C. difficile disease (CDTA–/ICD9+) (categories not mutually exclusive)
| Treatment | CDTA+, n = 662 (%) | CDTA–/ICD9+, n= 239 (%) | Odds ratio | p value |
|---|---|---|---|---|
| Any treatment for CDAD | 607 (92) | 214 (90) | 0.78 | 0.35 |
| Metronidazole | 591 (89) | 187 (78) | 0.43 | <0.01 |
| Oral vancomycin | 130 (20) | 75 (31) | 1.87 | <0.01 |
| Oral vancomycin and metronidazole | 114 (17) | 48 (20) | 1.21 | 0.32 |
Page created: November 10, 2011
Page updated: November 10, 2011
Page reviewed: November 10, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Content Credential